Abstracts tagged "glucocorticoids and osteoporosis"

Abstract Number: 1818 • 2018 ACR/ARHP Annual Meeting
Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Osvaldo D. Messina⁵, Jorge Morales-Torres⁶, Ronald Emkey⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aries, Argentina, ⁶Hospital Aranda de la Parra, Leon, Mexico, ⁷Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Denosumab 60 mg subcutaneously every 6 months (Q6M) increased spine and hip BMD significantly more than risedronate 5 mg orally once daily (QD) at…
Abstract Number: 2299 • 2018 ACR/ARHP Annual Meeting
Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals
Kenneth Saag¹, Nicola Pannacciulli², Piet Geusens³, Jonathan D. Adachi⁴, Eric Lespessailles⁵, Jorge Malouf⁶, Bente Langdahl⁷, Peter W. Butler², Xiang Yin² and Willem F. Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Aarhus University, Aarhus, Denmark, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…
Abstract Number: 2313 • 2018 ACR/ARHP Annual Meeting
The Efficacy of Denosumab for Prevention of Osteoporotic Fractures in Patients with Connective Tissue Diseases Receiving Very High Doses of Glucocorticoid
Keiichiro Kadoba, Keisuke Nishimura, Hiroki Mukoyama, Rintaro Saito, Daisuke Waki and Toshihiko Yokota, Department of Endocrinoligy and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan
Background/Purpose: Osteoporosis is a common complication of glucocorticoid therapy, contributing to significant morbidity especially in patients receiving very high doses of glucocorticoid (GC). There have…
Abstract Number: 2330 • 2018 ACR/ARHP Annual Meeting
Vitamin D and Bisphosphonate Therapy in SLE Patients Who Receive Glucocorticoids: Are We Offering the Best Care?
Smarika Sapkota¹, Sara Baig², Toy Hess³, Ann Marie O'Connell⁴, Jeremiah Menk³, Parastoo Fazeli⁵ and Anna K. Shmagel⁶, ¹Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, ²Department of Internal Medicine, University of Minnesota, Minneapolis, MN, ³University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minnepolis, MN, ⁵Rheumatology, University of Minnesota, Minneapolis, MN, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN
Background/Purpose: Glucocorticoids(GC) are frequently used for the treatment of systemic lupus erythematosus (SLE), and glucocorticoid induced osteoporosis (GIOP) is a well-known complication of long term…
Abstract Number: 331 • 2017 ACR/ARHP Annual Meeting
Case Series: Comparison of Repository Corticotropin Injection (H.P. Acthar Gel) Versus Glucocorticoids on Bone Density in SLE Patients
Anny T. Wu¹ and Joshua June², ¹Rheumatology, Franciscan Alliance, Munster, IN, ²3394 E Jolly Rd Ste C, Great Lakes Center of Rheumatology, Lansing, MI
Background/Purpose: Repository Corticotropin Injection (RCI) is an adrenocorticotropin hormone in 16% gelatin with a prolonged release after intramuscular (IM) or subcutaneous injection. Adverse effects of…
Abstract Number: 1888 • 2017 ACR/ARHP Annual Meeting
Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 12 Months in Subgroups of Glucocorticoid-Treated Individuals
Kenneth Saag¹, N Pannacciulli², P Geusens³, J Adachi⁴, Eric Lespessailles⁵, J Malouf⁶, O Messina⁷, AT Wang², Rachel B. Wagman² and WF Lems⁸, ¹University of Alabama, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵University Hospital Orleans, Orleans, France, ⁶Hospital San Pablo, Barcelona, Spain, ⁷Cosme Argerich Hospital, Buenos Aries, Argentina, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. We previously demonstrated that denosumab (DMAb) significantly increased lumbar spine (LS) BMD…
Abstract Number: 2L • 2016 ACR/ARHP Annual Meeting
Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
K Saag¹, RB Wagman², P Geusens³, JD Adachi⁴, O Messina⁵, R Emkey⁶, R Chapurlat⁷, NS Daizadeh², N Pannacciulli² and WF Lems⁸, ¹University of Alabama at Birmingham, Birmingham, AL, USA, Birmingham, AL, ²Amgen Inc., Thousand Oaks, CA, ³Maastricht University, Maastricht, Netherlands, ⁴McMaster University, Hamilton, ON, Canada, ⁵Cosme Argerich Hospital, Buenos Aires, Argentina, ⁶Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, ⁷Hôpital Edouard Herriot, Lyon, France, ⁸VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. Despite approved therapies, many subjects do not receive GIOP prevention or treatment.…
Abstract Number: 364 • 2015 ACR/ARHP Annual Meeting
Very High Frequency of Fragility Fractures Associated with High-Dose Glucocorticoids in Postmenopausal Women: A Retrospective Study
Goichi Kageyama¹, Takaichi Okano¹, Yuzuru Yamamoto¹, Keisuke Nishimura¹, Daisuke Sugiyama², Jun Saegusa¹, Goh Tsuji³, Shunichi Kumagai⁴ and Akio Morinobu¹, ¹Department of Rheumatology, Kobe University Hospital, Kobe, Japan, ²Department of Preventive Medicine and Public Health, Keio University, Tokyo, Japan, ³The Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, ⁴The Center of Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: To evaluate the incidence of fragility fractures associated with high-dose glucocorticoid therapy in patients with systemic rheumatic disease.Methods: A retrospective study of patients who were treated with high-dose…
Abstract Number: 368 • 2015 ACR/ARHP Annual Meeting
The Effects of Monitoring on a Quality Indicator for Glucocorticoid–Induced Osteoporosis and Trends of the Drug Variation in a Japanese Hospital
Masei Suda¹, Masato Okada¹, Yasuhiro Suyama², Mitsumasa Kishimoto¹ and Tokutaro Tsuda¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Rheumatology, JR Tokyo General Hospital, Tokyo, Japan
Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is one of the most clinically significant side effects of glucocorticoid use, and the prevention of GIOP has become more important…
Abstract Number: 233 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Marker Levels of Wnt/ß-Catenin Signaling Pathway in Patients with Systemic Autoimmune Diseases Under Glucocorticoid Therapy; A Prospective Study
Mai Kawazoe, Kotaro Shikano, Kaichi Kaneko, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including systemic autoimmune diseases. Although glucocorticoids improve the outcome for patients with these diseases,…
Abstract Number: 2256 • 2014 ACR/ARHP Annual Meeting
Effects of Pre-Dosage Alendronate Treatment on Bone Metabolic Indices and Bone Mineral Density in Patients Treated with Glucocorticoids: A Prospective Study
Yasuo Kuroki¹, Hiroshi Kaji², Mika Yamauchi³ and Toshitsugu Sugimoto⁴, ¹Dept of Internal Medicine, Kobe Century Memorial Hospital, Kobe, Japan, ²Department of Physiology and Regenerative Medicine, Kinki University Faculty of Medicine, Osakasayama, Japan, ³Internal Medicine 1, Shimane University Faculty of Medicine, Izmo, Japan, ⁴Internal Medicine 1, Shimane University Faculty of Medicine, Izumo, Japan
Background/Purpose: Glucocorticoids (GCs) treatment induces secondary osteoporosis characterized by rapid bone loss and an increase in fracture risk, although GCs are used to treat a…
Abstract Number: 2264 • 2014 ACR/ARHP Annual Meeting
Denosumab for Long-Term Glucocorticoid Users Who Have Inadequate Response to the Bisphosphonates: A 12-Month Randomized Control Trial
Chi Chiu Mok¹, Ling Yin Ho¹ and Kwok Man Ma², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Nuclear Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose To evaluate the efficacy of denosumab on bone mineral density (BMD) in long-term glucocorticoid users who have inadequate response to oral bisphosphonate treatment.Methods Patients…
Abstract Number: 1241 • 2013 ACR/ARHP Annual Meeting
A Low Serum 25(OH) Vitamin D Level As a Risk Factor For Incidence and Severity Of Vertebral Fracture In Glucocorticoid-Induced Osteoporosis In Japan
Mari Ushikubo¹, Harumi Kuda¹, Sayaka Kubo¹, Keisuke Izumi², Kumiko Akiya¹ and Hisaji Oshima¹, ¹Department of Connective Tissue Diseases, National Tokyo Medical Center, Tokyo, Japan, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although levels of serum 25(OH) vitamin D (25(OH)D) have been discussed for preventing osteoporotic fractures in primary osteoporosis, an importance of the levels has…
Abstract Number: 2059 • 2012 ACR/ARHP Annual Meeting
The Efficacy of Clinical Guidelines in Promoting Co-Prescription of Bone Protection with Glucocorticoids Among Hospital Doctors Treating Inpatients
Leonard C. Harty¹, James Clare², Dylan Finnerty², Susan Van Der Kamp², Fionnuala Kennedy³, Malachi McKenna⁴ and Oliver M. FitzGerald¹, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ³Pharmacy Department, St. Vincent's University Hospital, Dublin, Ireland, ⁴Department of Endocrinology & Metabolic Bone Disease, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Therapeutic glucocorticoids (GC) rapidly decrease bone mineral density, inducing a remodelling imbalance by promoting osteoclast differentiation and activation and by inhibiting oscteocytes. Current guidelines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].